Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Inositol treatment of obsessive-compulsive disorder.

Fux M, Levine J, Aviv A, Belmaker RH.

Am J Psychiatry. 1996 Sep;153(9):1219-21.

PMID:
8780431
2.

Controlled trials of inositol in psychiatry.

Levine J.

Eur Neuropsychopharmacol. 1997 May;7(2):147-55.

PMID:
9169302
3.

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH.

Am J Psychiatry. 1995 Jul;152(7):1084-6.

PMID:
7793450
4.
5.

Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial.

Seedat S, Stein DJ.

Int Clin Psychopharmacol. 1999 Nov;14(6):353-6. Erratum in: Int Clin Psychopharmacol 2000 Jul;15(4):244.

PMID:
10565802
6.

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Gamel NN.

J Clin Psychiatry. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. Epub 2009 Jun 30.

PMID:
19573497
7.

Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.

Palatnik A, Frolov K, Fux M, Benjamin J.

J Clin Psychopharmacol. 2001 Jun;21(3):335-9.

PMID:
11386498
8.

Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.

Stein DJ, Andersen EW, Overo KF.

Rev Bras Psiquiatr. 2007 Dec;29(4):303-7.

9.

Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.

Koran LM, Sallee FR, Pallanti S.

Am J Psychiatry. 1997 Mar;154(3):396-401.

PMID:
9054789
10.

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS.

Arch Gen Psychiatry. 1990 Jun;47(6):577-85.

PMID:
2112374
11.

Inositol treatment of autism.

Levine J, Aviram A, Holan A, Ring A, Barak Y, Belmaker RH.

J Neural Transm (Vienna). 1997;104(2-3):307-10.

PMID:
9203092
12.

Fluvoxamine treatment of obsessive-compulsive disorder.

Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R.

Am J Psychiatry. 1987 Dec;144(12):1543-8.

PMID:
3120604
13.

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.

J Clin Psychiatry. 2005 Jun;66(6):736-43.

PMID:
15960567
14.
15.

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH.

Arch Gen Psychiatry. 2000 Aug;57(8):794-801.

PMID:
10920469
16.

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.

Arch Gen Psychiatry. 1994 Apr;51(4):302-8.

PMID:
8161290
17.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
18.

Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.

Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M.

J Clin Psychiatry. 2010 Jun;71(6):784-92. doi: 10.4088/JCP.09m05911blu. Epub 2010 May 4.

PMID:
20492845
19.

Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.

Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.

J Clin Psychiatry. 2011 May;72(5):716-21. doi: 10.4088/JCP.09m05266gre. Epub 2010 Aug 10.

PMID:
20816027
20.

Effect of inositol on bulimia nervosa and binge eating.

Gelber D, Levine J, Belmaker RH.

Int J Eat Disord. 2001 Apr;29(3):345-8.

PMID:
11262515

Supplemental Content

Support Center